Intervacc AB (DE:2E9)

FRANKFURT:2E9

2E9

Intervacc AB

RESEARCH TOOLSreports

Intervacc AB (2E9) Price & Analysis

0 Followers

2E9 Stock Chart & Stats

€0.05

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.05

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.01 - €0.11

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€26.84M

Enterprise Value€132.21M

Total Cash (Recent Filing)€160.89M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.35

Next Earnings

May 13, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding340,813,200

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.00

Price to Sales (P/S)13.68

P/FCF Ratio-4.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)€4.79M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetNear-zero debt materially reduces interest burden and financial distress risk, giving management durable flexibility to prioritize R&D, regulatory work or commercial investments. Over months this conservatism preserves optionality and lowers refinancing pressure versus highly levered peers.

Recent High Revenue GrowthA large reported revenue increase indicates meaningful commercial traction in the veterinary market. If sustained, elevated top-line growth supports scale benefits, improves the opportunity to spread fixed costs across volumes, and underpins a path toward margin recovery over several quarters.

Niche Veterinary Vaccine FocusA concentrated product strategy in livestock and bacterial vaccines builds domain expertise and regulatory know-how, creating barriers to entry. Structural demand for animal health and recurring vaccine need among producers supports more predictable, long‑lived revenue streams than one-off products.

Bears Say

Persistent Unprofitability And 2025 Gross LossA large gross loss in 2025 despite revenue growth signals structural margin deterioration or adverse product economics. Persistent operating losses reduce time to breakeven prospects and indicate deeper commercial or cost issues that may take multiple quarters to correct.

Consistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow imply reliance on external funding to sustain operations. Even with low debt, ongoing cash burn limits strategic flexibility, increases dilution risk from future raises or partnerships, and raises execution risk over the next several quarters.

Eroding Equity Base From Accumulated LossesDeclining equity from cumulative losses weakens the capital cushion that supports R&D and manufacturing scale. Over time this erosion can constrain financing options, reduce resilience to setbacks, and increase vulnerability to adverse industry or regulatory events.

2E9 FAQ

What was Intervacc AB’s price range in the past 12 months?

Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.

What is Intervacc AB’s market cap?

Intervacc AB’s market cap is €26.84M.

When is Intervacc AB’s upcoming earnings report date?

Intervacc AB’s upcoming earnings report date is May 13, 2026 which is in 37 days.

How were Intervacc AB’s earnings last quarter?

Intervacc AB released its earnings results on Feb 17, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.005 by -€0.004.

Is Intervacc AB overvalued?

According to Wall Street analysts Intervacc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intervacc AB pay dividends?

Intervacc AB does not currently pay dividends.

What is Intervacc AB’s EPS estimate?

Intervacc AB’s EPS estimate is >-0.01.

How many shares outstanding does Intervacc AB have?

Intervacc AB has 340,813,200 shares outstanding.

What happened to Intervacc AB’s price movement after its last earnings report?

Intervacc AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.005. Following the earnings report the stock price went up 43.75%.

Which hedge fund is a major shareholder of Intervacc AB?

Currently, no hedge funds are holding shares in DE:2E9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.